Delayed rejection of soluble tumor necrosis factor receptor-secreting tumor allografts

Transplantation

Volumn 65, Issue 1, 1998, Pages 113-120

  Sabatine, Marc S ^a   Laufer, Terri ^b   Glimcher, Laurie H ^b   Widmer, Michael ^c   Winn, Henry ^a   Auchincloss Jr , Hugh ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; CYTOKINE RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; GENETIC TRANSFECTION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOMODULATION; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; GENE THERAPY; GRAFT REJECTION; GRAFT SURVIVAL; H-2 ANTIGENS; HAPLOTYPES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; SOLUBILITY; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031886022     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199801150-00022     Document Type: Article

References (78)

1. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987; 262: 6951.
2. Jones EY, Stuart DI, Walker NPC. Structure of tumour necrosis factor. Nature 1989; 338: 225.
3. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959.
4. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717.
5. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666.
6. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon, and interleukin-1. Nature 1986; 323: 86.
7. Steffen M, Ottmann OG, Moore MAS. Simultaneous production of tumor necrosis factor-α and lymphotoxin by normal T cells after induction with IL-2 and anti-T3. J Immunol 1988; 140: 2621.
8. Pober JS, Gimbrone MA, Lapierre LA. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor and immune interferon. J Immunol 1986; 137: 1893.
9. Carlos T, Kovach N, Schwartz B. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: ELAM-1 and VCAM-1. Blood 1991; 77: 2266.
10. Neumann B, Machleidt T, Lifka A, et al. Crucial role of 55-kilodalton TNF receptor in TNF-induced adhesion molecule expression and leukocyte organ infiltration. J Immunol 1996; 156: 1587.
11. Wang B, Kondo S, Shivji GM, Fujisawa H, Mak TW, Saunder DN. Tumor necrosis factor receptor II (p75) signaling is required for the migration of Langerhans' cells. Immunology 1996; 88: 284.
12. Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci USA 1986; 83: 446.
13. Chang RJ, Lee SH. Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of an Ia antigen on a murine macrophage cell line. J Immunol 1986; 137: 2853.
14. Jasinski M, Wieckiewicz J, Ruggiero I, Pituch-Noworolska A, Zembala M. Isotype-specific regulation of MHC class II gene expression in human monocytes by exogenous and endogenous tumor necrosis factor. J Clin Immunol 1995; 15: 185.
15. Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T cell responses. J Immunol 1987; 138: 1786.
16. Yokota S, Geppert TD, Lipsky PE. Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-α. J Immunol 1988; 140: 531.
17. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA. Recombinant tumor necrosis factor induces procoagulant activity in cultures of human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533.
18. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740.
19. Farrah T, Smith CA. Emerging cytokine family. Nature 1992; 358: 26.
20. Loetscher H, Pan YCE, Lahm HW, et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990; 61: 351.
21. Schall TJ, Lewis M, Koller KJ, et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1990; 61: 361.
22. Smith CA, Davis T, Anderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019.
23. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumor necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5: 392.
24. Rothe J, Gehr G, Loetscher H, Lesslauer W. Tumor necrosis factor receptors: structure and function. Immunol Res 1992; 11: 81.
25. Grell M, Scheurich P, Meager A, Pfizenmaier K. TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res 1993; 12: 143.
26. Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74: 845.
27. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NFκB activation. Cell 1995; 81: 495.
28. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994; 78: 681.
29. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505.
30. Hsu H, Hunag J, Shu H-B, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4: 387.
31. Peetre C, Thysell H, Grabb A, Olsson I. A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol 1988; 41: 414.
32. Olsson I, Lants M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989; 42: 270.
33. Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989; 264: 11966.
34. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531.
35. Gatanaga T, Hwang C, Kohr W, et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990; 87: 8781.
36. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excess tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845.
37. Smith C, Davis T, Wignall J, et al. T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem Biophys Res Commun 1991; 176: 335.
38. Upton C, Macen J, Schreiber M, McFadden G. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 1991; 184: 370.
39. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151(3): 1548.
40. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7: 515.
41. Ulich TR, Yi ES, Yin S, Smith C, Remick D. Intratracheal administration of endotoxin and cytokines. VII. The soluble interleukin-1 receptor and the soluble tumor necrosis factor receptor II (p80) inhibit acute inflammation. Clin Immunol Immunopathol 1994; 72: 137.
42. Quinn TD, Miller FN, Wilson MA, et al. Interleukin-2 induced lymphocyte infiltration of multiple organs is differentially suppressed by soluble tumor necrosis factor receptor. J Surg Res 1994; 56: 117.
43. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151: 6602.
44. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995; 84: 433.
45. Van Zee KJ, Moldawer LL, Oldenburg HSA, et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol 1996; 156: 2221.
46. Mosley B, Beckmann MP, March CJ, et al. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 1989; 59: 335.
47. Harada N, Castle BE, Gorman DM, et al. Expression cloning of a cDNA encoding the murine interleukin 4 receptor based on ligand binding. Proc Natl Acad Sci USA 1990; 87: 857.
48. Jacobs CA, Lynch DH, Roux ER, et al. Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor. Blood 1991; 77: 2396.
49. Winn HJ. National Cancer Institute 1960. Monograph no. 2, vol. 113.
50. Gorer P. Some reactions of H-2 antibodies in vitro and in vivo. Ann N Y Acad Sci 1958; 73: 707.
51. Mitchison NA. Studies in the immunological response to foreign tumor transplants in the mouse. J Exp Med 1955; 102: 157.
52. Winn HJ. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 1961; 81: 228.
53. Potter H. Transfection by electroporation. In: Ausubel FM, Brent R, Kingston FE, et al., eds. Current protocols in molecular biology. New York: John Wiley & Sons, Inc., 1994.
54. Selden RF. Stable transfer of genes into mammalian cells. In: Ausubel FM, Brent R, Kingston FE, et al., eds. Current protocols in molecular biology. New York: John Wiley & Sons, Inc., 1994.
55. Hu-Li J, Ohara J, Watson C, Tsang W, Paul WE. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol 1989; 142: 800.
56. Dialynas DP, Quan ZS, Wall KA, et al. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal Ab GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 1983; 131: 2445.
57. Sarmiento M, Glasebrook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block cell-mediated cytolysis in the absence of complement. J Immunol 1980; 125: 2665.
58. Ghobrial RRM, Boublik M, Winn HJ, Auchincloss HJ. In vivo use of monoclonal antibodies against murine T cell antigens. Clin Immunol Immunopathol 1989; 52: 486.
59. Auchincloss HJ, Ghobrial RRM, Russell PS, Winn HJ. Anti-L3T4 in vivo prevents alloantibody formation after skin grafting without prolonging graft survival. Transplantation 1988; 45: 1118.
60. Ozato K, Sachs DH. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. J Immunol 1981; 126: 317.
61. Molossi S, Clausell N, Sett S, Rabinovitch M. ICAM-1 and VCAM-1 expression in accelerated cardiac allograft arteriopathy and myocardial rejection are influenced differently by cyclosporine A and tumor necrosis factor-α blockade. J Pathol 1995; 176: 175.
62. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats. Transplantation 1990; 50: 189.
63. Imagawa DK, Millis JM, Seu P, et al. The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation 1991; 51: 57.
64. Stevens HPJD, van der Kwast TH, van der Meide PH, Vuzevski VD, Buurman WA, Jonker M. Synergistic immunosuppressive effects of monoclonal antibodies specific for interferon-gamma and tumor necrosis factor alpha. Transplantation 1990; 50: 856.
65. Farney AC, Xenos E, Sutherland DER, et al. Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant Proc 1993; 25: 865.
66. Eason JD, Wee S, Kawai T, et al. Inhibition of the effects of TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors. Transplantation 1995; 59: 300.
67. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145.
68. Palladino MA, Shalaby MR, Kramer SM, et al. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 1987; 138: 4023.
69. Havell EA, Fiers W, North RJ. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 1988; 167: 1067.
70. Waksman BH. The pattern of rejection in rat skin homografts and its relation to the vascular network. Lab Invest 1963; 12: 46.
71. Dvorak HF, Mihm MC, Dvorak AM, Barnes BA, Manseau EJ, Galli SJ. Rejection of first-set skin allografts in man: the microvasculature is the critical target of the immune response. J Exp Med 1979; 150: 322.
72. Jooste SV, Colvin RB, Soper WD, Winn HJ. The vascular bed as the primary target in the destruction of skin grafts by antiserum. I. Resistance of freshly-placed skin grafts to antiserum. J Exp Med 1981; 154: 1319.
73. Jooste SV, Colvin RB, Winn HJ. The vascular bed as the primary target in the destruction of skin grafts by antiserum. II. Loss of sensitivity to antiserum in long-term xenografts of skin. J Exp Med 1981; 154: 1332.
74. Fisher CH, Opal SM, Dhainaut JF, et al. Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21: 318.
75. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
76. Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJC. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs: a potential approach for preventing xenograft rejection. Transplantation 1995; 59: 1325.
77. Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B. Expression of a TNF inhibitor in transgenic mice. J Immunol 1993; 151: 5699.
78. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174: 1483.